StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)

Equities researchers at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report issued on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.

Minerva Neurosciences Stock Down 1.9 %

NERV opened at $2.10 on Monday. Minerva Neurosciences has a twelve month low of $2.07 and a twelve month high of $13.49. The company has a market cap of $14.68 million, a PE ratio of -4.86 and a beta of 0.18. The company has a 50-day moving average price of $2.57 and a 200 day moving average price of $2.79.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.